1-{(R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1,2,4]triazol-1-yl)-ethanone | 1967811-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-{(R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1,2,4]triazol-1-yl)-ethanone
• 英文别名: 1-[(2R)-2-(2-hydroxyethyl)-4-[2-(trifluoromethyl)-4-[2-(trifluoromethyl)pyrimidin-5-yl]-1,3-thiazol-5-yl]piperazin-1-yl]-2-(3-methyl-1,2,4-triazol-1-yl)ethanone
• CAS: 1967811-46-6
• 化学式: C₂₀H₂₀F₆N₈O₂S
• 分子量: 550.488
• InChiKey: FDZFVXKCJKOSRC-CYBMUJFWSA-N

物化性质

• 沸点：
  647.5±65.0 °C(Predicted)
• 密度：
  1.65±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  (3-methyl-[1,2,4]triazol-1-yl)-acetic acid benzyl ester 在 palladium on activated charcoal 、 氢气 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 1-{(R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1,2,4]triazol-1-yl)-ethanone
  参考文献：
  名称：

  Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c00074

文献信息

• HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：EP3245203A1

  公开（公告）日：2017-11-22
• [EN] HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE L'HYDROXYALKYL PIPÉRAZINE UTILISÉS COMME MODULATEURS DU RÉCEPTEUR CXCR3
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016113344A1

  公开（公告）日：2016-07-21

  The invention relates to compounds of Formula (I) wherein n, X, R1 and R2 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.
• [EN] CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE<br/>[FR] FORME CRISTALLINE D'UN DÉRIVÉ DE PIPÉRAZINYL-THIAZOLE
  申请人：[en]IDORSIA PHARMACEUTICALS LTD

  公开号：WO2022162017A1

  公开（公告）日：2022-08-04

  The invention relates to a crystalline form of 1-(R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1,2,4]triazol-1-yl)-ethanone, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline form, pharmaceutical compositions prepared from such crystalline forms, and their use as CXCR3 receptor modulators in the treatment of various diseases and disorders related to the CXCR3 receptor and its ligands.